Haloperidol increases DOPAC in the substantia nigra but not in the ventral tegmental area.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D002421:Caudate Nucleus / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D010648:Phenylacetates / Q000378:metabolism*; D051381:Rats; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*; D013681:Tegmentum Mesencephali / Q000378:metabolism*; D013997:Time Factors
D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D006220:Haloperidol